Parametric Portfolio Associates LLC grew its stake in Inogen, Inc (NASDAQ:INGN) by 63.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. Insiders own 5.31% of the company's stock.
Several other large investors have also added to or reduced their stakes in the company. Nationwide Fund Advisors now owns 80,007 shares of the medical technology company's stock valued at $7,609,000 after purchasing an additional 1,950 shares in the last quarter.
Inogen (NASDAQ INGN) opened at $117.37 on Tuesday. Teacher Retirement System of Texas boosted its position in shares of Inogen by 40.3% in the second quarter. Curbstone Financial Management Corp now owns 22,460 shares of the medical technology company's stock valued at $2,136,000 after purchasing an additional 10,505 shares in the last quarter. Following the completion of the transaction, the executive vice president now directly owns 4,833 shares of the company's stock, valued at $308,345.40. Finally, Curbstone Financial Management Corp lifted its holdings in shares of Inogen by 87.9% during the 3rd quarter.
The company is up by 2.68% since yesterday's close of 114.19. Inogen, Inc has a 12 month low of $60.02 and a 12 month high of $124.90.
The following firms have recently changed their position in INGN. The brokerage set a "strong-buy" rating on the medical technology company's stock. The company's P/E ratio is 82.88 and the market cap is 2.46B. BidaskClub downgraded Inogen from a "strong-buy" rating to a "buy" rating in a report on Monday, July 31st.
Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, November 7th.
Separately, Zacks Investment Research raised Inogen from a "hold" rating to a "buy" rating and set a $67.00 price objective for the company in a research report on Tuesday, October 4th. The medical technology company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.03. On November 8 Leerink Swann kept the company rating at "Outperform" projecting a price of $120.00. Inogen had a return on equity of 13.37% and a net margin of 11.36%.
September 12 investment analysts at Piper Jaffray Companies maintained a company rating of "Hold" targeting a price of $90.00. The firm had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. During the same quarter previous year, the business posted $0.13 EPS. The company's revenue for the quarter was up 26.8% compared to the same quarter last year. research analysts expect that Inogen, Inc will post 1.19 EPS for the current year. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company. Inogen presently has an average rating of "Buy" and an average price target of $103.14. The shares were sold at an average price of $91.67, for a total value of $1,283,380.00. The stock was sold at an average price of $61.64, for a total value of $1,646,157.84.
Traders are a little more bullish on shares of the company lately if you put credence in the decrease in short interest. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Raymond Huggenberger sold 14,000 shares of the business's stock in a transaction dated Tuesday, August 15th. The disclosure for this sale can be found here. Following the transaction, the insider now directly owns 66,050 shares of the company's stock, valued at $4,071,322.